Get started
Author

Keiko Shoji

Observed names: K Shoji, K. Shoji, Keiko SHOJI
Observed institution: The University of Tokyo
OpenAlex ID: A5113623340
PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2008 · Katsutoshi Oda, Jennifer Okada, et al. · Cancer Research · 186
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
2009 · K Shoji, K Oda, et al. · British Journal of Cancer · 153
Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
2012 · Keiko Shoji, Katsutoshi Oda, et al. · PLoS ONE · 78
PDF
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
2014 · Tomoko Kashiyama, Katsutoshi Oda, et al. · PLoS ONE · 50
PDF
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway
2010 · S Murayama-Hosokawa, K Oda, et al. · Oncogene · 44
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report
2010 · Keiko Shoji, Katsutoshi Oda, et al. · Medical Oncology · 24
Abstract 4494: In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
2011 · Keiko Shoji, Katsutoshi Oda, et al. · Cancer Research · 7
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
2011 · K. Oda, K. Shoji, et al. · Journal of Clinical Oncology · 6
Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
2010 · K. Shoji, K. Oda, et al. · Journal of Clinical Oncology · 4
Reply: Somatic mutations are present in all members of the AKT family in endometrial carcinoma
2009 · K Shoji, K Oda, et al. · British Journal of Cancer · 4
PDF
Supplementary Tables 1-5 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 1 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Data from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 2 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 4 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 3 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 5 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Methods from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Supplementary Figure 4 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
PDF
Supplementary Figure 6 from PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
2023 · Katsutoshi Oda, Jennifer Okada, et al.
Abstract 525: Induction of apoptosis in ovarian clear cell carcinomas with wild-type TP53 by inhibiting PI3K/mTOR signaling pathway.
2013 · Tomoko Kashiyama, Katsutoshi Oda, et al. · Cancer Research
Abstract 1702: A novel diagnostic approach using genome-wide single nucleotide polymorphism arrays for ovarian metastases in endometrial cancers
2012 · Yuji Ikeda, Katsutoshi Oda, et al. · Cancer Research
Genome-wide single nucleotide polymorphism (SNP) arrays as a novel diagnostic tool in synchronous carcinomas.
2011 · Y. Ikeda, K. Oda, et al. · Journal of Clinical Oncology
Abstract 2957: Mutations of Cyclin D1 / beta-catenin are coexistent with mutations in Ras-PI3K pathway genes in endometrial cancer
2011 · Yuji Ikeda, Katsutoshi Oda, et al. · Cancer Research
Abstract 3139: Chromosomal copy number alterations involved in Ras/PI3-kinase pathway in endometrial carcinomas
2010 · Yuji Ikeda, Katsutoshi Oda, et al. · Cancer Research
Works count: 28
Citation count: 556
H-index: 7
I10-index: 6
Year
Topic
Type